What is Clarix Imaging?
Clarix Imaging operates at the intersection of medical technology and oncology, specializing in intraoperative volumetric specimen imaging. Its flagship product, the VSI-360, provides surgeons with unprecedented 3D clarity, specifically engineered for breast surgical oncology. By enabling the direct visualization of lumpectomy specimen margins through high-resolution tissue slices, the company addresses a critical gap in current surgical workflows. This technology is designed to reduce re-excision rates and improve overall patient outcomes, positioning Clarix as a vital player in the precision medicine landscape. The company leverages decades of research to deliver practical, high-impact imaging tools that empower healthcare institutions to achieve superior clinical results.
How much funding has Clarix Imaging raised?
Clarix Imaging has raised a total of $10M across 1 funding round:
Not Disclosed
$10M
Not Disclosed (2023): $10M, investors not publicly disclosed
Key Investors in Clarix Imaging
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Clarix Imaging?
With this major enterprise-level funding, Clarix Imaging is poised to scale its commercial operations and expand the reach of its VSI-360 platform. The strategic roadmap likely involves deepening market penetration within major oncology centers and potentially diversifying its imaging portfolio to address broader surgical applications. As the company transitions from a research-heavy entity to a commercial-stage leader, the focus will remain on clinical validation and the integration of its imaging systems into standard-of-care protocols. Investors are closely monitoring the firm's ability to maintain its technological edge while navigating the complex regulatory and procurement environments inherent to the medical device industry.
See full Clarix Imaging company page
